comparison of glp-1 agonists for weight loss Comparing GLP-type therapies in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults comparison of glp 1 agonists
Description
Welchs two-sample t-test and Fishers exact tests were used for the continuous and categorical variables respectively
12 (2000): 68746879, 10.1073/pnas.120069197
Emmerich SD et al
S., ODonovan, B., Ortinski, P
41 This finding was consistent with oral semaglutide, with mild-to-moderate gastrointestinal adverse events being the most commonly reported events in clinical trials
In a clinical trial involving 112 patients, administration of the GLP-1 analogue exenatide led to a 21% faster reduction in blood lactate levels within 6 hours compared to placebo (95% CI: 6.0%33%
